Engineered virus-mimicking nanovaccine with lymph node–tumor dual-targeting and STING-activating capacity for robust cancer immunotherapy
Journal of Controlled Release · 2025-02 · 378 · 416-427
DOI: 10.1016/j.jconrel.2024.12.034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-02. Verfasst von Zhongjie Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Technology, Beijing Institute of Technology, Beijing 100081, PR China. Hauptthemen laut MEDLINE: Cancer Vaccines, Membrane Proteins, Neoplasms, Nucleotides, Cyclic. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China, Science Fund for Distinguished Young Scholars of Tianjin Municipality.
Abstract (Originalsprache)
Cancer vaccines have garnered considerable interest for cancer immunotherapy. However, their effectiveness is limited by inadequate proliferation, activation, and tumor infiltration of cytotoxic T lymphocytes (CTLs). Inspired by the potent immunostimulatory properties of viral components and the exposure of calreticulin during immunogenic cell death (ICD) triggered by viral infections; in this study, we describe cGAMP@vEVs, a virus-mimicking nanovaccine strategy by engineering tumor cell-derived extracellular vesicles through virus infection, which co-load both personalized and broad antigen repertoire as well as multiple immune adjuvants to potently elicit antitumor immunity. We demonstrate that cGAMP@vEVs exhibit both the commendable lymph node-tumor dual-targeting and stimulator of interferon genes (STING) pathway-activating capacity, which drive the proliferation and activation of tumor-specific CD8+ T cells in lymph nodes. Simultaneously, cGAMP@vEVs actively accumulate to tumor sites, and ameliorate immunosuppression tumor microenvironment, promoting the spontaneous tumor infiltration of CTLs. The coactivation of the immune response and TME reinitiate the self-sustaining cycle of cancer immunity, therefore efficiently inhibiting tumor progression, metastasis, and recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medical Technology, Beijing Institute of Technology, Beijing 100081, PR China.
- State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Enginee…
- Center for Child Care and Mental Health (CCCMH), Shenzhen Children's Hospital, Shenzhen 518034, PR China. Electronic address: lu_guihong@163.com.
- School of Medical Technology, Beijing Institute of Technology, Beijing 100081, PR China. Electronic address: llhuang@bit.edu.cn.
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Science Fund for Distinguished Young Scholars of Tianjin Municipality
- Natural Science Foundation of Hebei Province
- Beijing Institute of Technology Research Fund Program for Young Scholars
Zitieren
APA
Wang, Z., Liu, S., Ming, R., Wang, W., Wang, C., Li, C., Yang, J., Zhang, F., Lu, G., Mei, L., & Huang, L. L. (2025). Engineered virus-mimicking nanovaccine with lymph node–tumor dual-targeting and STING-activating capacity for robust cancer immunotherapy. Journal of Controlled Release, 378, 416-427. https://doi.org/10.1016/j.jconrel.2024.12.034
Vancouver
Wang Z, Liu S, Ming R, Wang W, Wang C, Li C, et al. Engineered virus-mimicking nanovaccine with lymph node–tumor dual-targeting and STING-activating capacity for robust cancer immunotherapy. Journal of Controlled Release. 2025;378:416-427. doi:10.1016/j.jconrel.2024.12.034
BibTeX
@article{Wang2025,
author = {Wang, Zhongjie and Liu, Shujun and Ming, Ruiqi and Wang, Weiwei and Wang, Chenguang and Li, Chuyu and Yang, Jiahua and Zhang, Fan and Lu, Guihong and Mei, Lin and Huang, Li-Li},
title = {Engineered virus-mimicking nanovaccine with lymph node–tumor dual-targeting and STING-activating capacity for robust cancer immunotherapy},
journal = {Journal of Controlled Release},
year = {2025},
volume = {378},
pages = {416--427},
doi = {10.1016/j.jconrel.2024.12.034}
}
EUVIMED